Insmed, Inc. (NASDAQ:INSM) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Insmed, Inc. has received an average analyst rating of "Moderate Buy", with 16 out of 17 analysts recommending a buy.
• The company's stock price target has varied, with Bank of America raising it to $109, while Wells Fargo and Guggenheim set targets at $171 and $172, respectively.
• Insmed reported a quarterly loss of ($1.70) EPS, which was lower than analysts' expectations, despite an 18.9% year-over-year revenue increase to $107.42 million.

Shares of Insmed, Inc. (NASDAQ:INSM - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seventeen analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and sixteen have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $139.8571.

INSM has been the topic of several research reports. Bank of America raised their price objective on Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. Wells Fargo & Company raised their price objective on Insmed from $140.00 to $171.00 and gave the stock an "overweight" rating in a report on Wednesday, September 3rd. Guggenheim raised their price objective on Insmed from $125.00 to $172.00 and gave the stock a "buy" rating in a report on Monday, September 8th. Citigroup upgraded shares of Insmed to a "buy" rating in a research note on Tuesday, June 10th. Finally, Royal Bank Of Canada increased their target price on shares of Insmed from $108.00 to $120.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th.

Insmed Stock Up 0.1%

Insmed stock opened at $145.93 on Friday. Insmed has a fifty-two week low of $60.40 and a fifty-two week high of $149.08. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. The firm has a 50 day moving average price of $119.40 and a 200 day moving average price of $92.00. The company has a market capitalization of $30.85 billion, a PE ratio of -25.56 and a beta of 0.97.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The company had revenue of $107.42 million for the quarter, compared to analysts' expectations of $104.06 million. During the same period in the prior year, the company posted ($1.94) EPS. The firm's revenue was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. Research analysts expect that Insmed will post -4.56 earnings per share for the current year.

Insider Transactions at Insmed

In related news, CFO Sara Bonstein sold 58,400 shares of the firm's stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $102.67, for a total value of $5,995,928.00. Following the completion of the sale, the chief financial officer owned 73,505 shares in the company, valued at $7,546,758.35. This trade represents a 44.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Melvin Md Sharoky sold 10,000 shares of the stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $129.50, for a total transaction of $1,295,000.00. Following the completion of the transaction, the director directly owned 274,516 shares of the company's stock, valued at approximately $35,549,822. This trade represents a 3.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 378,382 shares of company stock valued at $40,169,038 over the last 90 days. Insiders own 3.00% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of INSM. Teachers Retirement System of The State of Kentucky purchased a new stake in Insmed in the 1st quarter worth approximately $975,000. OneDigital Investment Advisors LLC boosted its holdings in shares of Insmed by 47.1% in the 1st quarter. OneDigital Investment Advisors LLC now owns 5,226 shares of the biopharmaceutical company's stock valued at $399,000 after purchasing an additional 1,673 shares during the last quarter. Sowell Financial Services LLC acquired a new position in shares of Insmed in the 1st quarter valued at $255,000. GAMMA Investing LLC boosted its holdings in shares of Insmed by 62.0% in the 1st quarter. GAMMA Investing LLC now owns 1,009 shares of the biopharmaceutical company's stock valued at $77,000 after purchasing an additional 386 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP acquired a new position in shares of Insmed in the 1st quarter valued at $34,434,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.